317 related articles for article (PubMed ID: 27399600)
1. Remestemcel-L for the treatment of graft versus host disease.
Locatelli F; Algeri M; Trevisan V; Bertaina A
Expert Rev Clin Immunol; 2017 Jan; 13(1):43-56. PubMed ID: 27399600
[TBL] [Abstract][Full Text] [Related]
2. Remestemcel-L for acute graft-versus-host disease therapy.
Chen GL; Paplham P; McCarthy PL
Expert Opin Biol Ther; 2014 Feb; 14(2):261-9. PubMed ID: 24350681
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
4. Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease.
Mannon PJ
Expert Opin Biol Ther; 2011 Sep; 11(9):1249-56. PubMed ID: 21787241
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ
Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
8. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
Kurtzberg J; Prockop S; Chaudhury S; Horn B; Nemecek E; Prasad V; Satwani P; Teira P; Hayes J; Burke E;
Biol Blood Marrow Transplant; 2020 May; 26(5):855-864. PubMed ID: 32044400
[TBL] [Abstract][Full Text] [Related]
9. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F; Caballero-Velázquez T; López-Villar O; Redondo A; Parody R; Martínez C; Olavarría E; Andreu E; Prósper F; Díez-Campelo M; Regidor C; Villaron E; López-Corral L; Caballero D; Cañizo MC; Pérez-Simon JA
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1580-5. PubMed ID: 24952358
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
11. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease.
Daly A
Drugs Today (Barc); 2012 Dec; 48(12):773-83. PubMed ID: 23243634
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Steroid-Refractory Acute Graft-
Murata M; Teshima T
Front Immunol; 2021; 12():724380. PubMed ID: 34489977
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
14. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence.
Rizk M; Monaghan M; Shorr R; Kekre N; Bredeson CN; Allan DS
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1416-1423. PubMed ID: 27130504
[TBL] [Abstract][Full Text] [Related]
16. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.
Kebriaei P; Isola L; Bahceci E; Holland K; Rowley S; McGuirk J; Devetten M; Jansen J; Herzig R; Schuster M; Monroy R; Uberti J
Biol Blood Marrow Transplant; 2009 Jul; 15(7):804-11. PubMed ID: 19539211
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
[TBL] [Abstract][Full Text] [Related]
19. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.
Munneke JM; Spruit MJ; Cornelissen AS; van Hoeven V; Voermans C; Hazenberg MD
Transplantation; 2016 Nov; 100(11):2309-2314. PubMed ID: 26714122
[TBL] [Abstract][Full Text] [Related]
20. Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis.
Kuzmina LA; Petinati NA; Shipounova IN; Sats NV; Bigildeev AE; Zezina EA; Popova MD; Drize NJ; Parovichnikova EN; Savchenko VG
Eur J Haematol; 2016 Apr; 96(4):425-34. PubMed ID: 26115424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
